Rob Sterling Email & Phone Number

Helsinki, Southern Finland, Fi

Malmö, Se

Sever Pharma Services is a Malmo, Sweden based CDMO/CMO focused solely on Hot Melt Extrusion to create drug/polymer blends. Our process can enhance solubility of poorly soluble Active Pharmaceutical Ingredients, as well as use the high energy Melt Extrusion to improve compressibility in a continuous manufacturing process. Our extruders also blend API's with polymers to create local drug delivery solutions such as long term permanent or bioresorbable implants, films or fibers.

Lafayette, New York, Us

Cascade Biotechnology is an early stage private company with gene therapy and protein assets designed to deplete the Complement System. Our gene therapy program will first target Age Related Macular Degeneration while the protein program will address a range of immunologic disorders such as Rheumatoid Arthritis, Lupus and Paroxysmal Nocturnal Hemoglobinuria (PNH).

Marseille, Paca, Fr

Pursue pharmaceutical, device and chemical alliances and partnerships to take advantage of new standards and intellectual property of company's current asset, Methylene BlueManage the resulting alliances for relationship, performance and profitabilityNegotiate and sign license agreements that generate overall valueSeek opportunities for in-licensing or acquisition to improve both company, sister company and parent value.Oversee regulatory processes

Provide service to Biotech, Pharma and Animal Health Companies: Business Development Licensing and Sales, Corporate Development Financing and Strategic Planning, Investor Relations, Marketing and Tactical planning.

Us

• Created complete business, financial and development plans with correlating investment steps, coupled with budget and forecasts, through 2020. Structured turnkey business for immediate progression upon funding.• Prospected for available intellectual property for developmental and valuable commercial opportunity.• Signed license agreements that generate value creation and company exit at proof of concept, including initial, growth stage and late stage financing milestones • Pursue alliances and partnerships to create non-dilutive funding with 10 Big Pharma firms of which two remain interested and continue to receive updates. • Devised manufacturing agreement with creative financing to achieve milestones prior to qualified financing. • Filed 8 state program funding applications with incentives (ie. Cancer Prevention Research Institute of Texas)• Presented this funding opportunity to 30 personal investors/ family trusts and 60 angel/venture groups

• Led investor relations and business development and partnered with the CEO/Founder to grow firm from 2 to 34 employees in the US and Europe,• Positioned a successful company exit in sale to Genzyme for $345M in 2007 resulting from obtaining oncology drug approval in the US and Europe• Raised over $100M as a public company over a six year period in 4 financing rounds. • Arranged and held meetings with domestic and European investment fund managers and presented to more than 40 health care investor forums and large retail investment groups in the US. • Signed three out-license arrangements (1 Australia, 2 USA). Negotiated final terms for 3 Regional Co-Development or License agreements at time of merger (Pan-Asian territories, Europe, South/Latin America). • Presented 2 merger opportunities and 4 programs for acquisition to the CEO and Board, after leading due diligence and evaluating for market, scientific and cultural fit for in-licensing.Project Development:o Clofarabine: Directed phases of topical formulation development through Clinical Phase II with $1M Budget. Contracted for Intellectual Property (IP) filings in formulation and use.o Suvus: Led effort to file for Hepatitis C indication in Egypt. Provided market evaluations to Board of Directors in support of Developing Nation Strategy. Contracted for preclinical and clinical trials in support of the IP filings. Secured manufacturing for drug product and sought new source of GMP drug substance. o Trilostane: Created Scientific Advisory Board for hypercorticolism and contracted Principal Investigator for protocol development. Evaluated CRO proposals for selection. Established FDA Liaison Team for communications with FDA and created filing strategy. Evaluated reformulation companies for IP extension.

Director of Companion Animal Marketing (1997-2000) • Aided formation of new internal startup unit. Directed marketing to grow business from $10.5M to $23.5M through strategic growth and acquisition.• Repositioned two 18 year-old products to achieve 100% sales growth of $7M to $14M from 1997 to 2000, which included FDA label extension, bottle repackaging and delivery system, and marketing funds redirected to consumers. Resulted in 2 NAMA award winning campaigns: Safe-Guard’s Apple Cinnamon Advertisement and Panacur’s Iceberg Educational Tool. • Increased high volume, Panacur SKU margin from 28% to 40%. Produced financial and production forecasts. Managed market research activities and competitive intelligence. • Prepared 5-year strategic plan for $45M geriatric animal product launch and formulated package requirements. • Established new sales territories and oversaw initial staffing, expenses and sales objectives.• Negotiated to acquire companion animal businesses, products, and/or marketing rights. • Directed Equine e-Commerce program implementation and Regu-Mate (altrenogest) Equine global marketingSenior Sales Representative and Field Trainer (1991-1997)• Managed 3 territories with Animal Health Sales and Training responsibilities, including new hire field training.• Exceeded forecasted growth via specialized local promotions and advertising, sales/veterinarian product training, public presentations and demonstrations to clients and producers.

Bachelor Of Arts, Secondary Education, Physics And Math

Education record